Liberalization and protection: antidumping duties in the Indian pharmaceutical industry
In this paper we investigate whether antidumping (AD) actions in the Indian pharmaceutical industry have restricted trade from countries that were named to be dumping, or whether trade was diverted to other countries not named in these petitions. We found no evidence of trade diversion. It is bad news for consumers, as a restrictive trade policy translates into higher prices for the importing good. In a country where only 30% of the population can afford access to modern drugs, the trade effect due to AD laws must be carefully evaluated.
If you experience problems downloading a file, check if you have the proper application to view it first. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.
As the access to this document is restricted, you may want to look for a different version under "Related research" (further below) or search for a different version of it.
Volume (Year): 11 (2008)
Issue (Month): 2 ()
|Contact details of provider:|| Web page: http://www.tandfonline.com/GPRE19|
|Order Information:||Web: http://www.tandfonline.com/pricing/journal/GPRE19|
When requesting a correction, please mention this item's handle: RePEc:taf:jpolrf:v:11:y:2008:i:2:p:115-122. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Michael McNulty)
If references are entirely missing, you can add them using this form.